The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with multiple HER2-expressing advanced solid tumours. These positive outcomes mark the successful achievement of two secondary endpoints of the trial. In the primary analysis, Enhertu […]
Fisher Scientific, a global leader in serving science, unveiled its latest product, the Gibco OncoPro Tumoroid Culture Medium Kit to expedite development of novel cancer therapies. This product is distinguished as the first commercially available culture medium explicitly crafted for the expansion of patient-derived tumoroids, also known as cancer organoids, from various cancer indications. The […]
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a research collaboration with pharmaceutical giant Bristol Myers Squibb to advance the discovery of tumor targets. The collaboration aims to leverage MEDiC Life Sciences’ expertise in tumor target discovery using its scalable 3D tumor models and CRISPR functional genomics screens. In this partnership, […]
Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is engaged in developing small molecule therapeutics for aggressive cancers and rare tumors. On the other hand, Advaxis is focused on developing immunotherapies based on a technology that makes use of […]
Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another type of metastatic breast cancer. The supplemental biologics license application (sBLA) filed by Gilead Sciences is for using the breast cancer drug in adults having unresectable locally advanced or metastatic […]
Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of head and neck squamous cell carcinoma (HNSCC) both as a monotherapy and in combination with Merck’s pembrolizumab (KEYTRUDA). The fast track designation for the interleukin 2 (IL-2)-based biologic is in […]
Ayala Pharmaceuticals has been granted fast track designation for its oral gamma-secretase inhibitor AL102 by the US Food and Drug Administration (FDA) for the treatment of progressing desmoid tumors. AL102 is currently being assessed by the clinical-stage oncology company in the phase 2/3 RINGSIDE clinical trial in desmoid tumors. According to Ayala Pharmaceuticals, in Part […]
BriaCell Therapeutics has signed an exclusive licensing deal with the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment. sCD80 was developed originally by Suzanne Ostrand-Rosenberg from the Emeritus Faculty at UMBC. According to BriaCell Therapeutics, sCD80 was well-tolerated in animal models, and by […]
HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody. The phase 1 clinical trial in China is a multicenter, open-label study, which will assess HMPL-A83’s safety, tolerability, pharmacokinetics, and preliminary efficacy in […]
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed on Nasdaq, is focused on developing and delivering therapies against novel epigenetic targets for patients with different types of cancer. Through the deal, Ipsen gets access to Tazverik (tazemetostat), the […]
